Lead Product(s): Anakinra
Therapeutic Area: Rare Diseases and Disorders Product Name: Kineret
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).